Better Health for All

Benitec Biopharma's core business is the development of BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder.

Clinical trial data for BB-301 shows a 100% responder rate in Cohort 1 (6 patients) as of November 2025, with individual patients achieving clinically normal swallowing profiles and up to a 91% reduction in Sydney Swallow Questionnaire scores, indicating revolutionary health benefits. The company has reported minimal to no revenue, with $0 in Q1 FY2024 and Q1 FY2023, and $75 thousand in FY2023, none of which is from products with negative health outcomes. The safety record for BB-301 is strong, with the first six study subjects safely treated as of April 2025, and no serious adverse events reported for the initial subjects, with transient Grade 2 GERD resolving with medication. BB-301 has Orphan Drug Designation from the FDA and EMA, indicating it targets a rare disease, which often affects vulnerable populations. However, the company is not accepting expanded access requests for BB-301 outside of clinical trials, stating this is to avoid delaying broader patient access, which limits current reach. The company's R&D expenses were $18.3 million in FY 2025, and $3.4 million in Q1 FY2026, with total expenses of $41.8 million in FY 2025, indicating a very high percentage of investment in health innovation. The company conducts its clinical trials with oversight from an Independent Data Safety Monitoring Board (DSMB) and has submitted trial packages to Research Ethics Boards (REB) in Canada, demonstrating strong ethical conduct.

Fair Pay & Worker Respect

states that no regulatory actions, violations, fines, or compliance issues are mentioned for Benitec Biopharma.

No specific, concrete data points were found in the provided articles to assess the company against other KPIs for Fair Pay & Worker Respect, including living wage coverage, CEO-to-median-pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, turnover rates, insecure contract share, or health insurance coverage.

Fair Trade & Ethical Sourcing

No specific data points or evidence related to BNTC.US's fair trade and ethical sourcing practices, supply chain audits, labour incidents, traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend were found in the provided articles.

The articles either discussed the pharmaceutical industry generally or were unavailable.

Honest & Fair Business

Benitec Biopharma Inc. will restate its quarterly financial statements for the periods ended December 31, 2024, and March 31, 2025, due to errors in share-based compensation calculations from an incorrectly configured information recording system.

The company has a Whistleblower Protection and Non-Retaliation Policy that permits anonymous reports and applies to all employees, officers, directors, and subsidiaries. It also has an Anti-Corruption Policy. Three out of five board directors are independent.

Kind to Animals

No information regarding Benitec Biopharma Inc. (BNTC.US) or its practices related to animal welfare, animal testing, animal-derived ingredients, or wildlife conservation was found in the provided articles.

All articles focused on Amazon's operations and labor practices.

Planet-Friendly Business

No specific, concrete data points for Benitec Biopharma Inc. (BNTC.US) regarding its environmental performance, targets, or initiatives were found in the provided articles.

The articles primarily discuss sector-wide trends and aggregate data for the biotech and pharmaceutical industries, or focus on BNTC.US's financial and clinical trial results. Therefore, no KPIs related to Planet-Friendly Business can be scored for BNTC.US based on the given evidence.

Safe & Smart Tech

The company has not identified any material risks from known cybersecurity threats or prior cybersecurity incidents that have materially affected its operations, business strategy, results, or financial condition.

It maintains an information security program designed to manage risks and protect critical data, including intellectual property and patient-related data, and to prevent or mitigate data loss, theft, misuse, or other security incidents. The Audit Committee oversees cybersecurity risks, and senior leadership provides periodic reports. The company conducts regular security trainings for employees and senior management. It has implemented measures to protect personal information from accidental loss and unauthorized access, use, alteration, and disclosure. Users have rights to obtain, delete, correct, object to, or restrict processing of personal information, and can withdraw consent. They can also manage cookie preferences and opt out of promotional emails. The company states its cybersecurity policies include mechanisms to prevent or mitigate system intrusion or vulnerabilities and maintain a stable and secure IT environment. It also conducts ongoing monitoring of critical systems for compromised accounts. The company is subject to laws governing the privacy and security of health information and has obtained Orphan Drug Designation in the US and EU.